CoChat

Senolytics: Potential for Alleviating Diabetes and Its Complications

Open access
Palmer, Allyson K, Tchkonia, Tamar, Kirkland, James L · 2021 · Endocrinology
Cited by 46

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Abstract

Therapeutics that target cellular senescence, including novel “senolytic” compounds, hold significant promise for treating or preventing obesity-induced metabolic dysfunction, type 2 diabetes, and the multiple complications of diabetes and obesity. Senolytics selectively clear senescent cells, which accumulate with aging and obesity and represent a fundamental mechanism of aging that contributes to metabolic dysfunction and diabetes pathogenesis. In addition to improving metabolic function, targeting senescent cells holds promise as a preventive strategy to reduce the incidence and severity of diabetes complications. The intermittent administration schedule used for senolytic therapy may confer benefits in terms of improving adherence and limiting adverse effects. It is necessary to design effective clinical trials that will safely translate discoveries from preclinical models into human studies that may pave the way for a novel therapeutic class for treating obesity, diabetes, and their complications. In this review, we outline what is known regarding the role of cellular senescence in the pathogenesis of type 2 diabetes and its complications, present evidence from preclinical models that targeting cellular senescence is beneficial, review senolytic drugs, and outline the features of clinical trials investigating the role of targeting senescent cells for diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/endocr/bqab058

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Research works printed but not linked: 19

  1. Iske, 2020, Senolytics prevent mt-DNA-induced inflammation and promote the survival of aged organs following transplantation, Nat Commun., 11, 4289, 10.1038/s41467-020-18039-x · DOI · Paper page
  2. Coppé, 2010, The senescence-associated secretory phenotype: the dark side of tumor suppression, Annu Rev Pathol., 5, 99, 10.1146/annurev-pathol-121808-102144 · DOI · Paper page
  3. Minamino, 2009, A crucial role for adipose tissue p53 in the regulation of insulin resistance, Nat Med., 15, 1082, 10.1038/nm.2014 · DOI · Paper page
  4. Kim, 2020, Transplanted senescent renal scattered tubular-like cells induce injury in the mouse kidney, Am J Physiol Renal Physiol., 318, F1167, 10.1152/ajprenal.00535.2019 · DOI · Paper page
  5. Gustafson, 2019, Reduced subcutaneous adipogenesis in human hypertrophic obesity is linked to senescent precursor cells, Nat Commun., 10, 2757, 10.1038/s41467-019-10688-x · DOI · Paper page
  6. Garg, 2011, Clinical review#: lipodystrophies: genetic and acquired body fat disorders, J Clin Endocrinol Metab., 96, 3313, 10.1210/jc.2011-1159 · DOI · Paper page
  7. Kung, 2016, The role of the p53 tumor suppressor in metabolism and diabetes, J Endocrinol., 231, R61, 10.1530/JOE-16-0324 · DOI · Paper page
  8. Wu, 2018, Relevance of the p53-MDM2 axis to aging, Cell Death Differ., 25, 169, 10.1038/cdd.2017.187 · DOI · Paper page
  9. Huang, 2014, Role of p53 in preadipocyte differentiation, Cell Biol Int., 38, 1384, 10.1002/cbin.10334 · DOI
  10. Mitterberger, 2014, Adipogenic differentiation is impaired in replicative senescent human subcutaneous adipose-derived stromal/progenitor cells, J Gerontol A Biol Sci Med Sci., 69, 13, 10.1093/gerona/glt043 · DOI · Paper page
  11. Wang, 1995, Senescent human fibroblasts resist programmed cell death, and failure to suppress bcl2 is involved, Cancer Res., 55, 2284
  12. Olave, 2010, Upstream stimulatory factor-2 mediates quercetin-induced suppression of PAI-1 gene expression in human endothelial cells, J Cell Biochem., 111, 720, 10.1002/jcb.22760 · DOI · Paper page
  13. Bruning, 2013, Inhibition of mTOR signaling by quercetin in cancer treatment and prevention, Anticancer Agents Med Chem., 13, 1025, 10.2174/18715206113139990114 · DOI · Paper page
  14. Pignolo, 2020, Reducing senescent cell burden in aging and disease, Trends Mol Med., 26, 630, 10.1016/j.molmed.2020.03.005 · DOI · Paper page
  15. Christopher, 2008, Metabolism and disposition of dasatinib after oral administration to humans, Drug Metab Dispos., 36, 1357, 10.1124/dmd.107.018267 · DOI · Paper page
  16. Fox, 2017, The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia, Blood Adv., 1, 802, 10.1182/bloodadvances.2016003889 · DOI · Paper page
  17. Andres, 2018, Safety aspects of the use of quercetin as a dietary supplement, Mol Nutr Food Res., 62, 10.1002/mnfr.201700447 · DOI · Paper page
  18. Maher, 2015, How fisetin reduces the impact of age and disease on CNS function, Front Biosci (Schol Ed)., 7, 58, 10.2741/s425 · DOI · Paper page
  19. Kim, 2021, Metformin inhibits chronic kidney disease-induced DNA damage and senescence of mesenchymal stem cells, Aging Cell., 20, e13317, 10.1111/acel.13317 · DOI

Cited by

Metadata

Authors
Palmer, A. K., Tchkonia, T., & Kirkland, J. L.
Venue
Endocrinology
Published
2021-03-11
Volume
162
Issue
8
ISSN
  • 0013-7227 (ISSN-L)
  • 1945-7170
OpenAlex
W3135850494
Cited by
46
References
44
FWCI
4.44
Type
journal article
Language
en
Open access
hybrid
Funders
  • National Institutes of Health (R37AG013925, P01AG062413, R01AG 072301, R01DK120292)
  • Translational Geroscience Network (R33AG061456)
  • Alzheimer’s Association Part the Cloud Program
  • Robert and Arlene Kogod
  • Connor Group
  • Robert J. and Theresa W. Ryan
  • Noaber Foundation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.